An interventional study of Meloxicam in Inflammation, sponsored by Roxane Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Roxane Laboratories · Not applicable, Interventional, and Treatment
The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's enrollment of 47 is close to the median of 50 across 2,437 interventional studies indexed under Inflammation.
Browse Inflammation studies →Roxane Laboratories is the lead sponsor of 98 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Bioequivalence
Time frame: Baseline, Two period, Fourteen day washout
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Roxane Laboratories